May 17, 2019
Authored and Edited by Matthew J. Hlinka; M. Andrew Holtman, Ph.D.
On May 8, 2019, FDA issued draft guidance for the submission of documents using real-world data (RWD) and real-world evidence (RWE) to FDA for drugs and biologics. This draft guidance explains how RWD and RWE can be used as a part of regulatory submissions to FDA, and describes the information that should be included in those submissions.
RWD are data relating to the health status of a patient or to the delivery of health care to a patient. RWD are routinely collected from a number of sources, such as electronic health records, medical billing records, and mobile device applications. RWE is derived from the analysis of RWD, and can be used to demonstrate the usage and potential benefits or risks of a particular medical product.
The increasingly wide-spread availability of RWD, and the continued development of improved analytic techniques to generate RWE, has inspired the research and medical communities to use RWD and RWE to enhance clinical research and to support regulatory decision making. In response, FDA is currently evaluating the scope and use of RWE in IND, NDA, and BLA submissions relating to safety and effectiveness. To aid FDA’s evaluation, FDA encourages sponsors and applicants to identify submissions that include RWE tied to a specific product, and to provide information about the RWE used.
In each regulatory submission featuring RWE in support of safety or effectiveness, the sponsor or applicant should identify (1) the purpose for using RWE as part of the regulatory submission; (2) the design of any clinical study that includes RWE; and (3) all sources of RWD used to generate the RWE. This information should be highlighted in the submission’s cover letter or included in an accompanying table.
Readers are encouraged to read the draft guidance, also available on FDA's website.
Food and Drug Administration (FDA), drugs, FDA Guidance, Biologic License Application (BLA), new drug application (NDA)
Copyright © 2019 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.